FDA Approves Lilly’s Foundayo Oral GLP-1 Pill - Top_Thought_Leaders - MDSpire

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

  • By

  • Kathryn Wighton

  • April 1, 2026

  • 2 min

Share

Top Thought Leaders in Endocrinology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

  • by Kathryn Wighton

  • April 1, 2026

Related Content

Ultrasound omental fat as a precocious marker of metabolic adiposity in children

Cardiac magnetic resonance biomarkers for cardiovascular complications in diabetes: a systematic review and meta-analysis

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.